Clinical Trial Update: Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) [Phase 2]

View source ↗

Summary

This update describes a Phase 2 MATCH subprotocol evaluating larotrectinib (LOXO-101) in cancers with NTRK gene alterations; the trial status is currently Activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Malignant Neoplasm
• Multiple Myeloma

Drugs mentioned

• Larotrectinib (larotrectinib)
• Vitrakvi (larotrectinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING